Skye Bioscience, Inc. (SKYE)

Market Cap	26.26M -66.8%
Revenue (ttm)	n/a
Net Income	-51.23M
EPS	-1.29
Shares Out	32.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,896
Open	0.8113
Previous Close	0.7995
Day's Range	0.8000 - 0.8400
52-Week Range	0.6844 - 5.7500
Beta	2.82
Analysts	Strong Buy
Price Target	14.75 (+1,700.32%)
Earnings Date	Mar 19, 2026

About SKYE

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Die...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: SKYE
• Website: https://skyebioscience.com

Analyst Summary

According to 5 analysts, the average rating for SKYE stock is "Strong Buy." The 12-month stock price target is $14.75, which is an increase of 1,700.32% from the latest price.

Price Target

$14.75

(1,700.32% upside)

Analyst Consensus: Strong Buy